Skip to content

Does the use of intraoperative PVP-I (Povidone Iodine; Betadine) antiseptic wash in breast device surgery lower complication rates resulting in removal of the implants?

Intraoperative PVP-I (Povidone Iodine) antiseptic wash and complication rates in breast prosthesis surgery, analysis of observational Australian Breast Device Registry (ABDR) data

Status
Completed
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12623000114640
Enrollment
30245
Registered
2023-02-03
Start date
2021-09-24
Completion date
2021-09-24
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Evidence supports the use of intra-operative antiseptic rinse in breast implant surgery to minimize the risk of capsular contracture or other complications. However, there is limited consensus or standardization of antiseptic rinse in practice. Having already determined contemporary trends in antiseptic rinse use in primary breast device surgery in Australia, we will use observational Australian Breast Device Registry (ABDR) data to analyse antiseptic rinse effects on clinical outcomes.

Interventions

The intervention is the use of intraoperative betadine (Povidone-Iodine) pocket rinse. All surgeons and hospital sites registered with the ABDR continue to report any implant-related surgeries to the ABDR on an ongoing basis. Follow-up/outcomes data are made up of explantation (removal of implant) surgeries made necessary by the respective post-operative complications. All follow-up surgeries reported to the ABDR will be obtained up to 31 Dec 2022 from the ABDR, allowing for a 'rolling' minimu

The intervention is the use of intraoperative betadine (Povidone-Iodine) pocket rinse. All surgeons and hospital sites registered with the ABDR continue to report any implant-related surgeries to the ABDR on an ongoing basis. Follow-up/outcomes data are made up of explantation (removal of implant) surgeries made necessary by the respective post-operative complications. All follow-up surgeries reported to the ABDR will be obtained up to 31 Dec 2022 from the ABDR, allowing for a 'rolling' minimum follow-up period of 2 years. Patients are not required to do anything above their usual surgical treatment journey. The reporting of operative data is inherent in the ABDR national reporting processes.

Sponsors

Robert Knight
Lead SponsorIndividual

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Primary (First) Breast device surgery between 1 Jan 2015 to 31 Dec 2020 as reported to the ABDR

Exclusion criteria

Device revision surgeries Tissue expander insertion Tissue expander removal and implant insertion Concurrent mastectomy Axillary surgery including sentinel node biopsy Concurrent flap cover

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026